Clonixin

Identification

Summary

Clonixin is an NSAID used to relieve pain associated with arthritis, migraines, and various soft tissue disorders.

Generic Name
Clonixin
DrugBank Accession Number
DB09218
Background

Clonixin is a non-steroidal anti-inflammatory drug.

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 262.69
Monoisotopic: 262.0509053
Chemical Formula
C13H11ClN2O2
Synonyms
  • Clonixin
  • clonixino
External IDs
  • CBA 93626
  • SCH-10304

Pharmacology

Indication

Indicated for use in the management of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofMigraine••••••••••••••••••• ••••••
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Clonixin is a non-steroidal anti-inflammatory drug (NSAID) similar in structure to Diclofenac. It produces vasodilation and analgesia.

Mechanism of action

The mechanism of clonixin does not appear to have been investigated on a molecular level. It is presumed to function similarly to other NSAIDs by inhibiting cycloxygenase enzymes 1 and 2 resulting in a reduction in prostaglandin production.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirClonixin may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Abciximab.
AcebutololClonixin may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Clonixin.
AcemetacinThe risk or severity of adverse effects can be increased when Clonixin is combined with Acemetacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Clonixin lysine06PW4M190R55837-30-4CVNFYQCHAWFYQI-ZSCHJXSPSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
BENRELAX CÁPSULA BLANDAClonixin lysine (125 mg) + Cyclobenzaprine hydrochloride (5 mg)Capsule, liquid filledOralTECNOQUIMICAS S.A.2020-11-26Not applicableColombia flag
CLONIXINATO / CICLOBENZAPRINA 125MG/5MGClonixin lysine (125 mg) + Cyclobenzaprine hydrochloride (5 mg)Capsule, liquid filledOralTECNOQUIMICAS S.A.2020-11-26Not applicableColombia flag
DORIXINA® RELAX COMPRIMIDOS RECUBIERTOSClonixin lysine (125 mg) + Cyclobenzaprine hydrochloride (5 mg)Tablet, coatedOralMEGA LABS S.A.2006-11-10Not applicableColombia flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyridinecarboxylic acids. These are compounds containing a pyridine ring bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pyridinecarboxylic acids and derivatives
Direct Parent
Pyridinecarboxylic acids
Alternative Parents
Aniline and substituted anilines / Toluenes / Aminopyridines and derivatives / Chlorobenzenes / Aryl chlorides / Imidolactams / Vinylogous amides / Heteroaromatic compounds / Amino acids / Secondary amines
show 8 more
Substituents
Amine / Amino acid / Amino acid or derivatives / Aminopyridine / Aniline or substituted anilines / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzenoid
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organochlorine compound, aminopyridine, pyridinemonocarboxylic acid (CHEBI:76200)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
V7DXN0M42R
CAS number
17737-65-4
InChI Key
CLOMYZFHNHFSIQ-UHFFFAOYSA-N
InChI
InChI=1S/C13H11ClN2O2/c1-8-10(14)5-2-6-11(8)16-12-9(13(17)18)4-3-7-15-12/h2-7H,1H3,(H,15,16)(H,17,18)
IUPAC Name
2-[(3-chloro-2-methylphenyl)amino]pyridine-3-carboxylic acid
SMILES
CC1=C(NC2=C(C=CC=N2)C(O)=O)C=CC=C1Cl

References

General References
  1. Finch JS, DeKornfeld TJ: Clonixin: a clinical evaluation of a new oral analgesic. J Clin Pharmacol New Drugs. 1971 Sep-Oct;11(5):371-7. [Article]
KEGG Drug
D03555
PubChem Compound
28718
PubChem Substance
310265125
ChemSpider
26711
BindingDB
50201612
RxNav
2601
ChEBI
76200
ChEMBL
CHEMBL1332971
ZINC
ZINC000000001195
PDBe Ligand
6J3
Wikipedia
Clonixin
PDB Entries
5l4i / 6gnr
MSDS
Download (82.2 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
SolutionIntravenous100 mg
Capsule, liquid filledOral
SolutionParenteral100.000 mg
SolutionIntramuscular
TabletOral125.0000 mg
GelCutaneous5.000 g
SolutionIntramuscular100.000 mg
TabletOral125 mg
GelTopical5 g
SolutionIntravenous
Tablet, coatedOral
TabletOral125.00 mg
Solution100.000 mg
TabletOral125.000 mg
SolutionParenteral100 mg
TabletOral250.000 mg
SolutionParenteral
SolutionIntramuscular100.00 mg
TabletOral10.000 mg
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0535 mg/mLALOGPS
logP3.59ALOGPS
logP3.42Chemaxon
logS-3.7ALOGPS
pKa (Strongest Acidic)1.88Chemaxon
pKa (Strongest Basic)5.37Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area62.22 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity69.8 m3·mol-1Chemaxon
Polarizability25.98 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03ea-2590000000-f577010fed0b7319669b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-01ot-0090000000-43ad3b16631d2912e0ee
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0090000000-08cb6ee7512077d2a90b
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-01ot-0090000000-b139bd6211b1ec369918
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-1090000000-6a16d2c6d024c9d26b23
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ge9-0910000000-14efb5a5ffcaae5a8f97
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-3ba5bc92e62fe17757db
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-153.1681
predicted
DeepCCS 1.0 (2019)
[M+H]+155.52614
predicted
DeepCCS 1.0 (2019)
[M+Na]+161.61928
predicted
DeepCCS 1.0 (2019)

Drug created at October 21, 2015 17:14 / Updated at May 05, 2021 20:31